New hope for back pain: experimental drug LNK01001 enters final trial phase
NCT ID NCT07237568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the experimental drug LNK01001 can reduce pain and stiffness in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 352 participants will receive either LNK01001 or a placebo twice daily for 16 weeks, then everyone can receive the drug for another 36 weeks. The main goal is to see if more people on LNK01001 achieve at least a 40% improvement in symptoms compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Could a simple protein test unlock the secrets of joint disease?
- Can a biologic drug safely tame Back-Joint inflammation? a Real-World trial investigates
- New antibody aims to calm ankylosing spondylitis
- Can a 4-Minute chat rival a Dietitian's hour for heart health?
- Ultrasound and EMG may tell inflammatory from mechanical shoulder issues